Abstract: The invention concerns a method for stabilising particle size distribution of a powdery active principle, when the latter is dispersed in a liquid. Said method is characterised in that it consists in dispersing said active principle in a glycol ether or a mixture of glycol ethers. The invention also concerns the uses of said method and, in particular for pharmaceutical compositions and galenic forms comprising a retinoid as active principle, and suited for providing the latter with improved bioavailability (suprabioavailability) after oral administration.

Abstract: The invention relates to pharmaceutical dosage forms with rapid disintegration in the mouth and to their process of preparation. These pharmaceutical dosage forms comprise at least one active principle dispersed in a mixture of excipients and are characterized in that the mixture of excipients comprises at least one weakly compressible diluting agent other than trehalose and a copolymer of 1-vinylpyrrolidin-2-one and of vinyl acetate. Applications: oral administration of a great many active principles (analgesics, antispasmodics, agents used in gastroenterology, agents for combating motion sickness, antimigraines, &bgr;-blockers, antihistaminics, antibiotics or antibacterials, antivertigos, hypnotics, and the like).

Abstract: The invention relates to dispersible tablets containing macrolides as active ingredients either on their own or associated with other active ingredients, in addition to a method for the production thereof. The dispersible tablets are characterized in that the macrolide is chosen from a group that is made up of pristinamycin, azithromycin, roxithromycin, clarithromycin and spiramycin, and is present in a basic form in proportions ranging from 20-60% of the total weight of said tablets. The dispersible tablets are also characterized in that they contain at least one disintegrator in proportions ranging from 1-25% of the total weight of said tablets in addition to at least one sweetening agent.

Abstract: The invention relates to dispersible tablets containing macrolides as active ingredients either on their own or associated with other active ingredients, in addition to a method for the production thereof. The dispersible tablets are characterized in that the macrolide is chosen from a group that is made up of pristinamycin, azithromycin, roxithromycin, clarithromycin and spiramycin, and is present in a basic form in proportions ranging from 20-60% of the total weight of said tablets. The dispersible tablets are also characterized in that they contain at least one disintegrator in proportions ranging from 1-25% of the total weight of said tablets in addition to at least one sweetening agent.

Abstract: A pharmaceutical composition including a core of an NSAID selected from diclofenac and piroxicam which core is surrounded by a mantle coating of a prostaglandin, wherein an intermediate coating can be present between the NSAID core and prostaglandin mantle coating.